Vertex Pharmaceuticals Alpine Immune Sciences Acquisition 2024

Vertex Pharmaceuticals announced the acquisition of Alpine Immune Sciences for $4.9 billion in cash at $65 per share. The acquisition targets Alpine's lead asset povetacicept, a Phase 3-ready dual BAFF/APRIL inhibitor for immunoglobulin A nephropathy and other autoimmune kidney diseases. The transaction combines Vertex's development capabilities with Alpine's protein engineering and immunotherapy expertise.